Skip to main content
. 2020 Nov 2;5(1):34–40. doi: 10.1002/jgh3.12443

Figure 1.

Figure 1

Comparison of treatment efficacies between the ETV‐TAF and ETV groups. The median changes in the (a) HBsAg levels: (Inline graphic), ETV‐TAF; (Inline graphic), ETV; (b) ALT levels: (Inline graphic), ETV‐TAF; (Inline graphic), ETV, and (c) HBcrAg levels: (Inline graphic), ETV‐TAF; (Inline graphic), ETV. ALT, alanine aminotransferase; ETV, entecavir; HBcrAg, hepatitis B virus core‐related antigen; HBsAg, hepatitis B surface antigen; TAF, tenofovir alafenamide.